Kawai M, Kikkawa F, Hattori S, Ohta M, Arii Y, Tomoda Y
Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan.
Int J Gynaecol Obstet. 1994 Mar;44(3):259-66. doi: 10.1016/0020-7292(94)90176-7.
To determine the long-term outcomes of patients with epithelial ovarian cancer.
A group of 298 patients with epithelial ovarian cancer were treated with combination chemotherapy between July 1979 and January 1986 at the Tokai Ovarian Tumor Study Group. Long-term results of these patients were analyzed.
Five-year survival and 10-year survival rates of all the patients were 53% and 47%, respectively. Five-year survival and 10-year survival rates for stage I were 89% and 79%, 59% and 56% for stage II, 27% and 22% for stage III, and 9% and 9% for stage IV, respectively. Survival of mucinous and endometrioid cell types were decreased after 5 or more years. In stages II-IV, cisplatin-based chemotherapy produced better results than mitomycin-C, 5-Fu, cytarabine (MFC) therapy.
Long-term results of epithelial ovarian cancer were not favorable even in mucinous and endometrioid cell types. For long-term results, cisplatin-based chemotherapy was effective in advanced ovarian cancer. Long-term follow-up of ovarian cancer is important and necessary.
确定上皮性卵巢癌患者的长期预后。
1979年7月至1986年1月期间，东海卵巢肿瘤研究组对298例上皮性卵巢癌患者进行了联合化疗。分析了这些患者的长期结果。
所有患者的5年生存率和10年生存率分别为53%和47%。Ⅰ期的5年生存率和10年生存率分别为89%和79%，Ⅱ期为59%和56%，Ⅲ期为27%和22%，Ⅳ期为9%和9%。黏液性和子宫内膜样细胞类型的患者在5年或更长时间后的生存率下降。在Ⅱ - Ⅳ期，以顺铂为基础的化疗比丝裂霉素 - C、5 - 氟尿嘧啶、阿糖胞苷（MFC）疗法产生更好的效果。
即使是黏液性和子宫内膜样细胞类型的上皮性卵巢癌，长期预后也不理想。对于长期结果，以顺铂为基础的化疗对晚期卵巢癌有效。卵巢癌的长期随访很重要且必要。
